173 related articles for article (PubMed ID: 22752247)
1. Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors.
Chun YS; Yoshida T; Mori T; Huso DL; Zhang Z; Stearns V; Perkins B; Jones RJ; Sukumar S
Breast Cancer Res Treat; 2012 Aug; 135(1):201-8. PubMed ID: 22752247
[TBL] [Abstract][Full Text] [Related]
2. Ductal access for prevention and therapy of mammary tumors.
Murata S; Kominsky SL; Vali M; Zhang Z; Garrett-Mayer E; Korz D; Huso D; Baker SD; Barber J; Jaffee E; Reilly RT; Sukumar S
Cancer Res; 2006 Jan; 66(2):638-45. PubMed ID: 16423990
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
[TBL] [Abstract][Full Text] [Related]
4. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
5. Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin
Yokoe I; Omata D; Unga J; Suzuki R; Maruyama K; Okamoto Y; Osaki T
Drug Deliv; 2021 Dec; 28(1):530-541. PubMed ID: 33685314
[TBL] [Abstract][Full Text] [Related]
6. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
Grenader T; Goldberg A; Gabizon A
Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
[TBL] [Abstract][Full Text] [Related]
8. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical evaluation of intraductally administered agents in early breast cancer.
Stearns V; Mori T; Jacobs LK; Khouri NF; Gabrielson E; Yoshida T; Kominsky SL; Huso DL; Jeter S; Powers P; Tarpinian K; Brown RJ; Lange JR; Rudek MA; Zhang Z; Tsangaris TN; Sukumar S
Sci Transl Med; 2011 Oct; 3(106):106ra108. PubMed ID: 22030751
[TBL] [Abstract][Full Text] [Related]
10. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
[TBL] [Abstract][Full Text] [Related]
11. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies.
Kesterson JP; Odunsi K; Lele S
Chemotherapy; 2010; 56(2):108-11. PubMed ID: 20407236
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
13. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
[TBL] [Abstract][Full Text] [Related]
14. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
15. Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model.
Zhang Y; Li A; Wang Z; Han Z; He J; Ma J
J Drug Target; 2008 Nov; 16(9):679-87. PubMed ID: 18982516
[TBL] [Abstract][Full Text] [Related]
16. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
Krasner CN; Poveda A; Herzog TJ; Vermorken JB; Kaye SB; Nieto A; Claret PL; Park YC; Parekh T; Monk BJ
Gynecol Oncol; 2012 Oct; 127(1):161-7. PubMed ID: 22765965
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
[TBL] [Abstract][Full Text] [Related]
20. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
